AK Steel Holding Corporation (NYSE:AKS) reported adjusted net income and sales that beat analyst estimates. AK Steel reported a net loss of $7.2 million, or $0.05 per diluted share for the third quarter, compared with a net loss of $31.7 million, or $0.23 per diluted share, for the same quarter last year. The results reflect one-time costs associated with the acquisition of Severstal Dearborn, which AK Steel Holding Corporation (NYSE:AKS) completed on September 16, 2014. Excluding acquisition-related expenses, the steel manufacturer reported adjusted net income of $16.4 million, or $0.12 per diluted share.Analysts expected EPS of $0.09 per share, according to Capital IQ estimates. Revenue rose to $1.59 billion from $1.33 billion last year, ahead of projections of $1.49 billion. AK Steel said it would provide detailed guidance for its fourth quarter results in December. However, it said results will be affected by a planned outage at the company's Ashland Works blast furnace which began in late October and is expected to last approximately 28 days.Xcel Energy Inc (NYSE:XEL) received an investment-rating downgrade to hold from buy late Monday from Evercore ISI, even as the firm raised its target price on the utility operator's stock to $34.25 from $33. The action comes after the company last Thursday reported Q3 results that missed Street projections, hurt by weather impacts, but raised the low end of its full-year earnings view and projected 2015 earnings in line with the Street view. In a note to clients, Evercore ISI said Xcel Energy Inc (NYSE:XEL) "offers a competitive total return profile vs. other regulated utilities, but we think the stock is approaching fair value." It noted the new target price of $34.25 implies a 12-month total return of plus or minus 5%, saying "while that may be better than many of the other stocks in our regulated utility coverage universe given high current valuations, it no longer warrants a buy rating." XEL is trading in a 52-week range of $27.27 to $33.84.Aquinox Pharmaceuticals Inc (NASDAQ:AQXP), a clinical-stage pharmaceutical company discovering and developing targeted therapeutics for inflammatory disease and cancer, said its Q3 net loss almost doubled due to the costs of advancing drug trials. The net loss for the third quarter of 2014 was $6.3 million compared to a net loss of $3.4 million for the third quarter of 2013. Aquinox Pharmaceuticals Inc (NASDAQ:AQXP) said its FLAGSHIP trial, in patients with chronic obstructive pulmonary disease exacerbations, and its LEADERSHIP trial, in patients with bladder pain syndrome/interstitial cystitis are advancing towards completion. Aquinox had cash, cash equivalents, short-term and long-term investments of $48.1 million as of September 30, 2014, compared to $13.8 million as of December 31, 2013. The shares are trading with a 52-week range of $5.50 - $14.35.
Discover Hidden Gems
Don't miss the next big opportunity. Subscribe for timely alerts on potential market movers.
